Introduction {#S1}
============

Personalized medicine is a proactive medical approach, which in general seeks to stratify patients in risk groups and tailor treatments, medical decisions, health promotion, or preventive measures according to the individual's omics baseline profile combined with lifestyle and environmental factors ([@B1]). The advent of cost-effective next-generation sequencing (NGS) technologies, such as the sequencing of whole genomes (WGS), whole and clinical exomes (WES and CES), combined with the accumulation of genetic knowledge and easy-to-use bioinformatics tools, has paved the way for genomics-based personalized medicine into clinics ([@B18]; [@B9]; [@B6]; [@B30]; [@B3]; [@B33]). Nowadays, these technologies have already started to transform healthcare by enabling precise disease screening, actionable diagnostics, treatment, and management. Despite this, precision genomics has not been fully implemented in the vast majority of healthcare systems yet. In order to facilitate its implementation, practical and user-friendly workflows and pipelines are required.

In this study, we primarily aimed to describe a pipeline for balanced CES, WES, or WGS reporting of called variants in healthy individuals interested in proactive genetic testing. A batch of datasets taken from symptomatic patients was included only as a proof-of-principle. This approach of variant filtering helped us to initialize the process of implementing precision genomics in clinical practice at a tertiary healthcare institution ([Figure 1](#F1){ref-type="fig"}). By applying this workflow, we were expecting to find actionable variants of clinical relevance or variants that might aid reproductive decisions. Our current experience demonstrates that the implementation of genomic profiling following our filtering pipeline into real-life clinical practice can provide information of medical significance. The pipeline could be used in future systematic and longitudinal studies focusing on the translational aspects of genomic medicine.

![Operational and analytical workflows applied in this study. **(A)** Operational workflow starting with patient recruitment, pre-test genetic counseling, genome, or exome sequencing and bioinformatic analyses, representative sample of reports, and post-test genetic counseling. All adapted images used in this figure have a CC license. **(B)** Description of the analytical workflow for variant filtration.](fgene-11-00619-g001){#F1}

Materials and Methods {#S2}
=====================

Patients {#S2.SS1}
--------

We evaluated 94 patients meeting our inclusion/exclusion criteria with a median age of 34.5 years (range 2 to 65) of which 51/94 (54%) were males and 43/94 (46%) were females ([Table 1](#T1){ref-type="table"}). All individuals/patients were recruited at the Zan Mitrev Clinic either through regular pro-active check-ups or TV/social media. The sole inclusion criterion for symptomatic patients was a referral from a medical specialist; patients who were not able to provide written informed consent and complete medical history were excluded from the study. In addition, healthy individuals who were unable to provide written informed consent were excluded from the study ([Figure 1A](#F1){ref-type="fig"}). The analysis was done according to the workflow described in [Figure 1B](#F1){ref-type="fig"}. The vast majority of patients were of Macedonian descent 74/94 (78.72%), followed by Albanian 11/94 (11.70%), Serbian 4/94 (4.25%), American 3/94 (3.19%), Turkish 1/94 (1.06%), and Bulgarian 1/94 (1.06%). The aforementioned protocol was used only as a proof-of-principle for analyzing genetic data from symptomatic patients (*n* = 15); we only communicated the mutations associated with the clinical phenotype. In contrast, full reports following this protocol were disclosed to all healthy individuals (*n* = 79). Symptomatic patients were informed that additional unrelated information concerning their carrier status and pharmacogenetic profile could be provided as well. Although the WGS analysis has advantages over WES and CES in the respect of providing more comprehensive and uniform coverage of the whole genome, most of the patients 89/94 (94.7%) underwent WES or CES testing, due to cost-effectiveness.

###### 

Description of the cohort.

  ---------------------- ----------
  **Gender**             
  Male                   51 (54%)
  Female                 43 (46%)
  **Healthy/Affected**   
  Healthy                79 (84%)
  Affected               15 (16%)
  **Age**                
  \<18                   9 (10%)
  \>18                   85 (90%)
  **Method**             
  CES                    29 (31%)
  WES                    60 (64%)
  WGS                    5 (5%)
  ---------------------- ----------

Ethics Statement {#S2.SS2}
----------------

Written and signed informed consent for participation and publication of data was obtained from all subjects or their legal guardians (for patients under the age of eighteen) in this study. The ethics committee of the Zan Mitrev Clinic waived the need for IRB approval, deeming written and signed informed consent sufficient.

DNA Extraction, Library Preparation, NGS Sequencing {#S2.SS3}
---------------------------------------------------

Around 5 ml of whole blood was collected in K~2~-EDTA tubes, following accepted principles for blood drawing and blood collection. DNA was extracted from 400 μl of whole blood in a SaMag-12 automatic nucleic acid extraction system (Sacace Biotechnologies, Como, Italy), yielding between 5 and 15 μg of pure DNA, measured by NanoDrop spectrometry (A260/280 ratio 1.7--1.9). Clinical exome enrichment was carried out by using the TruSight One sequencing panel (Illumina, San Diego, United States) or in-house developed CES enrichment protocol (Sophia Genetics, Saint-Sulpice, Switzerland). Whole exome enrichment was carried out by using the SureSelect Human All Exon V6 kit (Agilent Technologies, Santa Clara, United States) or Human Core Exome kit (Twist Bioscience, San Francisco, United States). The entire wet lab work (DNA QC, enrichment, library preparation, and sequencing) for CES, WES, and WGS were carried out in the Sophia Genetics, Wuxi Nextcode or DNA link, or Beijing Genomics Institute facilities, respectively.

Primary Bioinformatic Analysis {#S2.SS4}
------------------------------

For CES, between 13 and 30 million reads were obtained with a NextSeq machine (Illumina, San Diego, United States), with a coverage of at least 50x for average 81% of all sequences. Sequence quality control was done with FastQC^[1](#footnote1){ref-type="fn"}^, and sequences were mapped to hg19 with BWA ([@B16]). single nucleotide variant (SNV) and indel calling, together with advanced variant annotation, were done with the Sophia DDM platform (Sophia Genetics, Saint-Sulpice, Switzerland).

For WES and WGS, between 40 and 120 million reads or ∼950 million were obtained with a HiSeq X--10 machine or NovaSeq 6000 (Illumina, San Diego, United States), respectively. The coverage of WES or WGS was \>75x or \>40x, respectively. Alignment, variant calling, and annotation were done on the Genoox platform (Palo Alto, United States).

All CES, WES, and WGS variant lists were additionally annotated with Annovar, which provides more annotation notes than Sophia Genetics and Genoox ([@B32]). All detected variants were taken into consideration in the subsequent filtering steps.

Secondary Bioinformatics Analysis, Filtering, and Interpretation of Variants {#S2.SS5}
----------------------------------------------------------------------------

The list of high confidence annotated variants was downloaded directly from the Sophia DDM/Genoox platforms in a.txt or.csv format and analyzed further in a spreadsheet program such as Microsoft Excel. In the primary variant-based selection step the entire list of variants was filtered (either in Excel or in-platform) based on ClinVar terms "pathogenic," "protective," "risk factor," and "drug response" followed by manual curation, manual filtration, and manual function attribution, and then distributed in the following categories: carrier status, cardiovascular disorders, hereditary cancer, pharmacogenetics, ACMG59 ([@B13]), immune diseases, diabetes, neurodegenerative and psychiatric disorders, uncategorized risks, and genome-wide association studies (GWAS; [@B17]).

As a secondary gene-based filtering approach, by using the "virtual panel" capability within the Sophia DDM/Genoox platforms, we have created an array of standardized virtual gene panels encompassing genes associated with (1) cardiovascular disorders, (2) hereditary cancer, (3) neurodegenerative and psychiatric disorders, (4) diabetes, (5) immune diseases, and (6) ACMG59 genes ([@B13]). The virtual gene lists per panel can be found in [Supplementary File S1](#FS1){ref-type="supplementary-material"}. Variants were selected from these virtual panels based on ACMG pathogenicity criteria ([@B27]) or computationally defined deleteriousness criteria (SIFT, Polyphen2, Mutation Taster, Mutation Assessor, FATHMM, dbscSNV Ada, GERP, GeneCanyon, and fitCons), and distributed in the above-mentioned categories.

Finally, in a third filtering variants of uncertain significance (VUS)-based approach, we selected all the non-sense/frameshift VUS in exons/splice donor-acceptor sites, and we reported them in the annex without further interpretation in order to make sure their significance is reassessed in the future when their function is determined ([Figure 1B](#F1){ref-type="fig"}).

All selected variants were evaluated (selected or discarded) according to information in ClinVar and literature^[2](#footnote2){ref-type="fn"}^. Also, further evaluation in other databases such as the human gene mutation database^[3](#footnote3){ref-type="fn"}^, CentoMD database ([@B29]), and Clinvitae^[4](#footnote4){ref-type="fn"}^ was carried out. Pathogenic variants, especially for medium and high penetrance alleles, were interpreted according to the latest available literature and ClinGen guidelines^[5](#footnote5){ref-type="fn"}^. Disease risk for non-Mendelian, lower-penetrance variants associated with common diseases was assessed based on GWAS. Typically, the odds ratio or relative risk was reported, or in rare cases *P*-value or chi-square statistic, respectively.

To increase the detection rate and minimize the rate of false positives, first, we applied the entire protocol for all detected variants (low and high confidence), and then we did the same only for high confidence retained variants. Retained variants had a quality score \>100, read depth \>10, and quality by depth \>10. To further reduce the level of false-positive variants, we retained only variants detected by multiple variant callers (GATK Haplotype Caller and FreeBayes). Alleles with a representation of \>25% of the total read coverage were defined as heterozygous. All discrepancies were solved by additional manual evaluation.

Patient Reports {#S2.SS6}
---------------

Concerning the bioinformatics strategies for data analysis, filtering, and interpretation, we wanted to strike a balance between under- and over-reporting of variants; in other words, we wanted to maximize the benefit of the provided genetic analysis while reducing the costs and unnecessary follow-ups. Patient reports were divided into two sections, main report and annex, following the same line of reasoning as described previously ([@B19]). The main report is typically 5--6 pages long and encompasses all the major findings (typically related to medium and high penetrance diseases), patient information, and methodology in a clear and concise language. In addition to the main report, we attached an annex consisting of 20--30 pages of all the selected (relevant) variants assigned to the above categories, in a tabular form accompanied with additional information such as:

1.  An in-depth reference to studies and major findings of the studies, especially for high penetrance alleles

2.  Odds ratio/relative risk/chi-square/*p*-value for common alleles (if available)

3.  Name of gene

4.  Type of variant (SNV, indel, etc.)

5.  Functional consequence (non-sense, missense, etc.)

6.  Genomic region (exonic, intronic, 5'UTR, etc.)

7.  Chromosome and chromosomal coordinates

8.  dbSNP or ClinVar rsID

9.  Population frequency (G1000, ExAC, esp5400)

10. ClinVar signature (pathogenic, benign, drug response, etc.). This section reports the overall interpretation of a variation based on aggregating data from submitters.

11. Inheritance (autosomal recessive, autosomal dominant, etc.)

12. Level of evidence in the pharmacogenetics section (based on^[6](#footnote6){ref-type="fn"}^ grading system)

Genetic Counseling {#S2.SS7}
------------------

All the patients underwent pre- and post-test genetic counseling. At the time of pre-test genetic counseling patients were informed about the potential implications of the genetic results to themselves and their families. We discuss the pros and cons of the test, and the current state of genetic/genomic research, as well as the basic principles of inheritance and penetrance. Following the test, we held in-depth discussions where the patients were reacquainted with the basics of DNA biology, genetic variants, types of inheritance, penetrance, and implications. With regard to common medical conditions and diseases, patients were told that these conditions are multifactorial and may include other known or unknown genetic, lifestyle, or environmental components. The genetic counselors stressed the meaning of phrases "no known pathogenic mutation causing/associated with \[name of condition\]" and the meaning and gravity of known pathogenic mutations.

Prior to testing, all of the patients signed written informed consent. All patients having actionable variants underwent a further examination or consultation with a relevant specialist. Hence, whenever mentioned further on that the patient was advised for a specific medical procedure, the advice came from relevant specialists and not the genetic counselors alone.

Results {#S3}
=======

In our efforts to provide the most relevant genomic information to our patients, we divided variants into two categories: variants of known significance (VKS) obtained from the filtering steps A and B and VUS obtained from the filtering step C. Out of the VKS basket, we only selected variants with a defined clinical value (e.g., high penetrance, level 1a/1b pharmacogenetic association, direct involvement in a clinically relevant pathway). Out of the VUS basket, we reported only variants fulfilling ACMG pathogenicity criteria in medium and high penetrance disease-causing genes. For better reporting, every filtered variant was distributed in a fitting category ([Figure 1B](#F1){ref-type="fig"}).

Evaluation of Known Variants {#S3.SS1}
----------------------------

### Carrier Status of Rare Diseases {#S3.SS1.SSS1}

By selecting genetic variants annotated as "pathogenic" or "likely pathogenic" in the ClinVar database, supplemented by further manual curation, available literature evaluation, and filtration of low-frequency variants, the rare disease carrier status of each patient for known variants was derived. The vast majority of patients (96.2%) were carriers of at least one known rare disorder/condition with some of them carrying multiple pathogenic variants, median = 4 ([Supplementary File S2](#FS2){ref-type="supplementary-material"}).

### Drug Response {#S3.SS1.SSS2}

Regarding "drug response," the list of variants was interpreted using information from the pharmGKB^[7](#footnote7){ref-type="fn"}^ database. Only level 1A and level 1B clinical annotations were added to the main report, while the rest of them remained in the annex. Most of the patients were carriers of multiple Level 1A/1B variants. For example, we observed that 34/94 (36.2%) patients were "poor/intermediate *CYP2D6* metabolizers," which is relevant for the metabolism of many drugs, including anti-depressants, opioids, and tamoxifen. In order to reduce the misclassification rate of CYP2D6 metabolizers, we are currently implementing approaches for the detection of *CYP2D6* (and other genes) copy number variants from WES data. In addition, 23/94 (24.5%) patients were "poor/intermediate *CYP2C19* metabolizers" highly relevant for antiplatelet therapy with clopidogrel, in line with observations from our cohort of \>3,000 patients ([@B14]). Similarly, 26/94 (27.7%) patients had a risk of statin-induced myopathy, with 2/26 (7.7%) being of a very high risk of myopathy and rhabdomyolysis as well ([Supplementary File S2](#FS2){ref-type="supplementary-material"}), in line with our internal observations from a cohort of \>1,500 patients.

### Actionable Variants Involved in Cardiovascular Diseases and Cancer {#S3.SS1.SSS3}

According to our protocol, we proceeded with the analysis of "actionable" variants ([Table 2](#T2){ref-type="table"} and [Supplementary File S2](#FS2){ref-type="supplementary-material"}). Interestingly, more than one third of healthy individuals were carriers of pathogenic/potentially pathogenic variants leading to different types of arrhythmias and hereditary cancer, which are known to have incomplete penetrance.

###### 

Representative list of patients with actionable variants.

  Patient   Associated conditions with gene                                        Gene (ClinVar)   Nucleotide          Protein        rsID          Clinvar signature (interpretation)
  --------- ---------------------------------------------------------------------- ---------------- ------------------- -------------- ------------- --------------------------------------------------------------------------------------------------------
  2         Congenital long QT syndrome                                            *KCNJ2*          c.566G \> T         p.Arg189Ile    rs199473381   Likely pathogenic(1)
  12        Long QT syndrome                                                       *KCNQ1*          c.914G \> C         p.Trp305Ser    rs120074186   Pathogenic(2);Likely pathogenic(1)
  29        Hereditary pancreatitis                                                *SPINK1*         c.101A \> G         p.Asn34Ser     rs17107315    Risk factor(2);Pathogenic(4);Uncertain significance(3)
            Cystic fibrosis; Hereditary pancreatitis                               *CFTR*           c.3154T \> G        p.Phe1052Val   rs150212784   Likely pathogenic(3);Pathogenic(2);Uncertain significance(4);Drug-response(1)
  30        Cardiac arrhythmia; Long QT syndrome                                   *ANK2*           c.11716C \> T       p.Arg3906Trp   rs121912706   Likely benign(4);Pathogenic(2);Uncertain significance(2)
  32        Malignant tumor of prostate; Hereditary cancer-predisposing syndrome   *MSR1*           c.877C \> T         p.Arg293\*     rs41341748    Pathogenic(1);Uncertain significance(3);Benign(1)
            Hereditary prostate cancer                                             *RNASEL*         c.793G \> T         p.Glu265\*     rs74315364    Pathogenic(1);Likely benign(1);Uncertain significance(1)
            Long QT syndrome                                                       *KCNE1*          c.253G \> A         p.Asp85Asn     rs1805128     Benign(5);Likely benign(5);risk factor(3);Pathogenic(1);Likely pathogenic(1);Uncertain significance(2)
  43        Thrombophilia, Thyroid cancer                                          *HABP2*          c.1601G \> A        p.Gly534Glu    rs7080536     Risk factor(2);Likely benign(1);Benign(1)
            Thrombophilia                                                          *F5*             c.A1601G            p.Q534R        rs6025        Pathogenic(4);Risk factor(4);Benign(1)
  52        Hereditary cancer risk                                                 *CHEK2*          c.470T \> C         p.Ile157Thr    rs17879961    Likely pathogenic(8);Pathogenic(9);Risk factor(3);Uncertain significance(2)
            MYH-associated polyposis; Hereditary cancer-predisposing syndrome      *MUTYH*          c.1437_1439delGGA   p.Glu480del    rs587778541   Pathogenic(14)
  56        Prothrombin deficiency, congenital; Thrombophilia                      *F2*             c.\*97G \> A                       rs1799963     Pathogenic(4);Risk factor(4)
            Thrombophilia                                                          *F5*             c.A1601G            p.Q534R        rs6025        Pathogenic(4);Risk factor(4);Benign(1)
  81        Hereditary cancer-predisposing syndrome                                *RAD50*          c.2801del           p.Asn934fs     rs748536322   Pathogenic(1)
  84        Hereditary cancer-predisposing syndrome                                *NBN*            c.511A \> G         p.Ile171Val    rs61754966    Benign(3);Likely benign(1);Uncertain significance(11);Pathogenic(1);Risk factor(1)
  91        Familial adenomatous polyposis                                         *APC*            c.3920T \> A        p.Ile1307Lys   rs1801155     Likely benign(1);Likely pathogenic(3);Pathogenic(1);Uncertain significance(10);Risk factor(9)
  92        Hereditary cancer risk                                                 *CHEK2*          c.470T \> C         p.Ile157Thr    rs17879961    Likely pathogenic(8);Pathogenic(9);Risk factor(3);Uncertain significance(2)
  94        Prothrombin deficiency, congenital; Thrombophilia                      *F2*             c.\*97G \> A                       rs1799963     Pathogenic(4);Risk factor(4)

The full table is given in

Supplementary File S2

. The asterisk denotes the variant in Clinvar

https://www.ncbi.nlm.nih.gov/clinvar/variation/13310/

.

For instance, patient 2 was a carrier of a pathogenic variant (c.566G \> T, p.Arg189Ile; rs199473381) in the *KCNJ2* gene, which has been associated with congenital long QT syndrome ([@B8]). Follow-up EKG revealed visible abnormalities in the heart rhythm and the patient underwent further diagnostics. Patient 20 harbored a rare pathogenic/likely pathogenic variant (c.839C \> T, p.Ala280Val; rs72552291) in the *GPD1L* gene that has been shown to decrease inward SCN5A Na + current and cause Brugada syndrome ([@B25]). The patient underwent a regular cardiac exam, and EKG showed no visible abnormalities; since the patient was taking lithium therapy (which could conceivably unmask Brugada syndrome), advice was given to discuss this with their clinical psychiatrist and cardiologist. Furthermore, in patient 32 we discovered a variant (c.253G \> A, p.Asp85Asn, and rs1805128) in the *KCNE1* gene that has been reported to be associated with long QT syndrome ([@B23]). During the post-test genetic counseling, the patient disclosed that a member of their close family had passed away "due to complications from arrhythmia." Other patients were also found to carry variants associated with long QT or other channelopathies; patient 12 and their parent carried a pathogenic variant (c.914G \> C; p.Trp305Ser; rs120074186) in the *KCNQ1* gene, whilst in patient 30 we identified a potentially pathogenic variant (c.5434C \> T; p.Arg1812Trp; rs121912706) in the *ANK2* gene associated with sudden death of the young ([@B20]). Finally, in patient 43 and patient 56 we found a combination of variants (Marburg I and *F5* Leiden, *F2* and *F5* Leiden, respectively) that might significantly increase the risk of thrombosis ([@B31]; [@B26]; [@B12]). All patients were advised to consult a specialist and conduct follow-up studies if deemed necessary.

In regard to cancer, in patient 52, we discovered the presence of variants (c.1437_1439delGGA, p.Glu480del, and rs587778541) in the *MUTYH* gene and (c.470T \> C, p.Ile157Thr, and rs1787996) in the *CHEK2* gene. The same *CHEK2* mutation was detected in patient 92. The variant in *MUTYH* is pathogenic and leads to MUTYH-Associated Polyposis in a recessive manner. The presence of the variant in a heterozygous format might slightly (1.5 times) increase the risk of colorectal cancer ([@B22]). The *CHEK2* variant has been reported to increase the risk of different types of cancer 2--3 times ([@B10]). The patient was advised to consult a specialist and discuss a screening protocol. Next, patient 84 harbored the variant (c.511A \> G, p.Ile171Val, and rs61754966) in the *NBN* gene, which is a low penetrance risk factor for cancer development ([@B7]); the patient reported having a family history of breast and pancreatic cancer. Finally, we detected a potentially pathogenic variant (c.3920T \> A, p.Ile1307Lys, and rs1801155) in the *APC* gene in patient 91 ([@B15]), who is currently undergoing follow-up diagnostics. All patients were advised to consult a specialist and conduct follow-up studies if deemed necessary.

Evaluation of Potentially Pathogenic Variants of Uncertain Significance (VUS) {#S3.SS2}
-----------------------------------------------------------------------------

By analyzing VUS with rare population frequency meeting ACMG pathogenicity criteria ([@B27]) we uncovered many VUS in medium- or high-penetrance genes ([Supplementary File S2](#FS2){ref-type="supplementary-material"}). For instance, patient 56 is a carrier of (c.2423A \> G, p.Tyr808Cys; rs746368140) in the *TGFBR3* gene. The involvement of the TGF-beta pathway has been reported in pathologies such as familial thoracic aortic aneurysm and dissection (familial TAAD; [@B21]). The father of patient 56 was diagnosed with a thoracic and abdominal aortic aneurysm and underwent valve-sparing root replacement (Tirone-David procedure). The patient was advised to follow regular cardiovascular check-ups. Patient 75 is a carrier of VUS (c.1755dupA, p.Glu586fs, and rs751465048) in the *MLH3* gene, which is part of the MMR machinery associated with Lynch syndrome ([@B24]). The patient already had benign tumors removed from their breast and nose, in the past. The patient was advised to consult a specialist. Finally, patient 84 is a carrier of (c.3145G \> A, p.Gly1049Ser, and rs778181932) in the *FBN1* gene, which could be possibly associated with TAAD; the patient reported a history of sudden death in their close family.

Discussion {#S4}
==========

The central tenet of personalized medicine is proactive care of patients based on the combined information and insights provided by omics approaches, lifestyle, environmental factors, and family history. To aid the implementation of precision genomics locally into our hospital, we have outlined a workflow centered around filtering, stratification in groups, and interpretation of genetic variants that can be readily applied in any genetic lab. By applying these strategies of variant-centric, gene-centric, and VUS-centric filtering, we were able to peer into the genetic constitution of 94 patients and make initial assessments of their carrier status, pharmacogenetics profile, and genetic risk of developing rare and common disorders.

Our experience demonstrates that the implementation of genomic profiling into real-life clinical practice can provide molecular and physiological information of medical significance, although many challenges remain to be addressed ([@B4]). To begin, serious efforts should be made to improve the knowledge of physicians and raise awareness for patients and the general public about the benefits and pitfalls of pre-emptive genomic testing, especially in the context of the current genetic knowledge. Second, standardization and defined guiding principles are necessary for both the technical and interpretational side of genomics in medicine. A list of guidelines (benchmarks) should be set for the minimal quality and coverage of sequencing data. For instance, currently WES is the most cost-effective approach, but it is limited to the protein-coding regions of the genome; as WGS sequencing costs continue to plummet this will likely lead to a rise in the popularity of WGS, which generates more uniform coverage of both coding and non-coding regions of the genome, relevant for monogenic as well as polygenic disorders. In addition, standardized algorithms for variant calling in clinical settings should be recommended. Moreover, more standardized approaches for filtering and distillation of relevant information, especially methods for calculation of polygenic scores, as well as balanced reporting of valuable information and VUS, and support tools for clinical interpretation, should be designed ([@B4]). Third, our analytical workflow based on filtering and virtual gene panels is readily applicable but still has a lot of space for improvement. For example, the virtual gene lists should undergo a process of constant curation and improvements from experts in the relevant subspecialties in order to get better informed, non-redundant, and more optimal lists of genes. Another limitation is that our focused study did not provide insights in regard to the cost-effectiveness of genetic testing, as well as the perceived value by both physicians and patients in a controlled and systematic manner. In order to objectively quantify the value of proactive genetic testing, longitudinal follow-up approaches are necessary.

Finally, many complex diseases, such as diabetes, cancer, and some neurological, cardiovascular, and psychiatric disorders, likely involve a large number of different genes and environmental factors ([@B11]; [@B2]; [@B5]; [@B28]). These caveats sometimes might lead to unnecessary follow-up diagnostic measures and wastefulness of resources. Currently, the greatest value of genomic approaches lies in the detection of lower frequency moderate to high penetrance variants, which are easier to interpret and are better characterized due to their more resonant effects ([@B6]).

In conclusion, by establishing a balanced filtering pipeline, we set the foundation for the integration of genomics in mainstream clinical practice. The valuable insights and experiences we have obtained can have a bearing in future systematic and longitudinal follow-up studies.
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ACMG59

:   incidental findings in 59 genes recommended by American College of Medical Genetics and Genomics

CES

:   clinical exome sequencing

GWAS

:   genome-wide association studies

indel

:   insertion or deletion

SNV

:   single nucleotide variant

VUS

:   variants of uncertain significance

WES

:   whole-exome sequencing

WGS

:   whole-genome sequencing.
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